AHA In Brief: Possis AngioJet
This article was originally published in The Gray Sheet
Executive Summary
Possis AngioJet: Thrombectomy device is "effective in removing thrombus with a low rate of distal embolization and other angiographic complications" in high-risk patients with and without acute myocardial infarction, clinical investigator Jeffrey Popma, MD, Washington Hospital Center, Washington D.C., says Nov. 10 at the AHA conference in Orlando. Popma presented 12-month data from 90 patients in the VeGAS I study showing a mortality rate comparable to that of conventional treatment. Most patients (90%) who received AngioJet therapy also had adjunctive intervention such as stent placement, the researcher reported. Investigators currently are compiling data from a 300-patient, randomized VeGAS II trial. Possis has an IDE pending at FDA to study the AngioJet for treating stroke caused by blockage in the carotid artery...